D. Nolan

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differences in Lipid Measurements by Antiretroviral Regimen Exposure in Cohorts from Asia and Australia

J. Amin, T. Sirisanthana, T. Merati, 2012, AIDS research and treatment.

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

Dominic Michael Dwyer, S. Emery, J. Amin, 2014, PloS one.

New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals.

I. James, S. Mallal, J. Montaner, 2020, Human immunology.

Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity reaction

S. Mallal, J. Montaner, M. Cavassini, 2007 .

External Quality Assessment of HLA-B*5701 Reporting: An International Multicentre Survey

S. Mallal, M. Gill, C. Mamotte, 2007, Antiviral therapy.

Pharmacogenetics and clinical characteristics of patch test confirmed patients with Abacavir hypersensitivity

S. Mallal, J. Montaner, S. Knowles, 2006 .

Supertype Motifs by HLA Class I Molecules with Common HIV-1: Highly Divergent Selection Imposed Adaptive Interactions between HLA and

D. Heckerman, R. Haubrich, M. John, 2010 .

Severe drug‐induced hypersensitivity syndrome with a shared HLA‐B allele

K. Subramaniam, D. Nolan, G. Macquillan, 2012, The Medical journal of Australia.

Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy?

D. Nolan, 2005, Drug safety.

Long-term Management of the HIV-infected Patient - Tailoring Highly Active Antiretroviral Therapy to Optimise Therapeutic Outcome

E. Martinez, D. Nolan, 2008 .

Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy

D. Nolan, E. Hammond, 2007, Current opinion in HIV and AIDS.

Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy

S. Mallal, D. Nolan, E. McKinnon, 2008, AIDS.

NRTI therapy is associated with mitochondrial DNA depletion, increased mitochondrial biogenesis and subcutaneous fat wasting in HIV infected patients

M. John, S. Mallal, D. Nolan, 2001 .

Mitochondrial Proliferation, Dna Depletion and Adipocyte Differentiation in Subcutaneous Adipose Tissue of HIV-Positive Haart Recipients

S. Mallal, C. Mamotte, Annalise M. Martin, 2002, Antiviral therapy.

Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors

I. James, D. Nolan, A. Castley, 2016, PloS one.

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

S. Fernandez, M. French, D. Nolan, 2014, Clinical & translational immunology.

Elevated Plasma Soluble CD14 and Skewed CD16+ Monocyte Distribution Persist despite Normalisation of Soluble CD163 and CXCL10 by Effective HIV Therapy: A Changing Paradigm for Routine HIV Laboratory Monitoring?

S. Fernandez, M. French, D. Nolan, 2014, PloS one.

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.

S. Mallal, A. Lucas, D. Nolan, 2007, The Journal of antimicrobial chemotherapy.

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients

I. James, S. Mallal, J. McCluskey, 2007, AIDS.

Antiretroviral-therapy-associated lipoatrophy: current status and future directions.

S. Mallal, D. Nolan, 2005, Sexual health.

Potential roles for uncoupling proteins in HIV lipodystrophy.

D. Nolan, C. Pace, 2004, Mitochondrion.

Antiretoviral Therapy and the Lipodystrophy Syndrome, Part 2: Concepts in Aetiopathogenesis

M. John, S. Mallal, D. Nolan, 2000, Antiviral therapy.

Getting to the HAART of insulin resistance.

S. Mallal, D. Nolan, 2001, AIDS.

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

D. Nolan, E. McKinnon, E. Hammond, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

F. Christiansen, D. Nolan, 2003, Antiviral therapy.

Abacavir hypersensitivity in HLA-B57-positive individuals with HIV infection is dependent upon the conventional MHC-I Ag presentation pathway

S. Mallal, J. McCluskey, J. Rossjohn, 2007 .

Cellular tropism of HIV-1 mediated and contrained by coreceptor dependencies

S. Mallal, A. Rauch, S. Gaudieri, 2005 .

Assessing the contribution of ART, HIV and host factors to adipose tissue changes occurring in HIV-infected individuals: Risk profile for lipoatrophy

S. Mallal, D. Nolan, E. McKinnon, 2005 .

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

S. Mallal, Annalise M. Martin, D. Nolan, 2003, AIDS.

Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level

I. James, S. Mallal, D. Nolan, 2002, Antiviral therapy.

Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

M. John, I. James, S. Mallal, 2001, AIDS.

Antiretroviral Therapy and the Lipodystrophy Syndrome

M. John, S. Mallal, D. Nolan, 2001, Antiviral therapy.

Genome-wide HLA-associated-selection in HIV-1 and protein-specific correlations with viral load: An ACTG5142 study

D. Heckerman, R. Haubrich, M. John, 2008 .

Highlighting The Role OF IgE Autoantibodies In Bullous Pemphigoid

M. John, S. Salman, D. Nolan, 2019, Pathology.

IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.

M. John, S. Salman, D. Nolan, 2019, Clinical immunology.

Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV‐infected adults?

M. Law, K. Petoumenos, J. Zhou, 2011, HIV medicine.

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*01 and higher CD4+ T cell counts

I. James, S. Mallal, E. Phillips, 2004 .

A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield: Results from the Perth CVID Cohort Study.

M. John, S. Tangye, L. D'Orsogna, 2022, The Journal of molecular diagnostics : JMD.

HIV: Experiencing the Pressures of Modern Life

I. James, S. Mallal, D. Nolan, 2005, Science.

Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN-g responses in PBMC from HIV-infected patients with abacavir or nevirapine hypersensitivity reactions

S. Mallal, D. Marriott, A. Kelleher, 2007 .

Thymidine analogue-sparing highly active antiretroviral therapy (HAART).

S. Mallal, D. Nolan, 2003, Journal of HIV therapy.

Abacavir stimulates Hsp70 redistribution in Antigen-presenting cells of patients with hypersensitivity: Association with Type-I alcohol dehydrogenase activity

I. James, S. Mallal, J. McCluskey, 2005 .

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.

M. John, I. James, S. Mallal, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Homozygosity Is Associated with an Impaired CD 4 T Cell Recovery after Initiation of Antiretroviral Therapy

M. John, I. James, S. Mallal, 2008 .

Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.

F. Christiansen, C. Witt, S. Mallal, 2005, Molecular immunology.

Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms

S. Mallal, D. Nolan, 2004, Antiviral therapy.

Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen–restricted immune pressure

M. John, I. James, S. Mallal, 2009, Hepatology.

Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy

I. James, S. Mallal, P. Klenerman, 2009, Hepatology.

Pre‐exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children

A. Bowen, C. Blyth, D. Nolan, 2019, The Medical journal of Australia.

Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.

F. Christiansen, S. Mallal, Annalise M. Martin, 2003, American journal of human genetics.

Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.

S. Mallal, J. Montaner, P. Reiss, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics

David Nolan, Peter Reiss, Simon Mallal, 2005, Expert opinion on drug safety.

Involvement of Apoptosis in complications of HIV and its treatment

D. Nolan, 2005 .

Subcutaneous fat tissue mitochondrial DNA depletion and adipose toxicity are strongly associated with nucleoside reverse transcriptase inhibitor (NRTI) therapy in HIV-infected patients

I. James, S. Mallal, D. Nolan, 2003 .

The immunological footprint of CMV in HIV-1 patients stable on long-term ART

P. Price, J. Affandi, Samantha Brunt, 2015, Immunity & Ageing.

Raised lactate levels are common and may be predictive of subcutaneous fat wasting

C. Moore, M. John, I. James, 2000 .

Association of MHC SNP genotype with susceptibility to type 1 diabetes: a modified survival approach

I. James, G. Morahan, D. Nolan, 2009, Diabetes, obesity & metabolism.

Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system.

S. Mallal, S. Gaudieri, D. Nolan, 2006, Current opinion in immunology.

Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins

Nebojsa Jojic, Tomer Hertz, David Nolan, 2010, Journal of Virology.

Constrained Pattern of Viral Evolution in Acute and Early HCV Infection Limits Viral Plasticity

M. John, I. James, S. Mallal, 2011, PloS one.

Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression

C. Moore, F. Christiansen, C. Witt, 2005, Genes and Immunity.

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

David Nolan, Nicholas A Williamson, James McCluskey, 2008, Immunity.

A national study of the molecular epidemiology of HIV-1 in Australia 2005–2012

A. Kelleher, B. Herring, D. Dwyer, 2017, PloS one.

Longitudinal Trends in Western Australian HIV-1 Sequence Diversity and Viral Transmission Networks and Their Influence on Clinical Parameters: 2000-2014.

M. John, I. James, S. Gaudieri, 2016, AIDS research and human retroviruses.

S. Mallal, O. Chassany, M. Duracinsky, 2013, Health and Quality of Life Outcomes.

Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice

D. Nolan, A. Castley, E. McKinnon, 2016, HIV medicine.

Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.

S. Mallal, S. Gaudieri, E. Phillips, 2004, Pharmacogenomics.

HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

C. Moore, I. James, C. Witt, 2022 .

Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

S. Mallal, A. Rauch, Annalise M. Martin, 2006, Pharmacogenomics.

Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground

M. John, S. Mallal, S. Gaudieri, 2004, AIDS.

Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6–12 months of commencing nucleoside reverse transcriptase inhibitor therapy

I. James, S. Mallal, D. Nolan, 2004, AIDS.

NK receptor haplotypes and HLA as predictors of HIV-1 progression

C. Moore, F. Christiansen, S. Mallal, 2004 .

The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort

I. James, F. Christiansen, F. Mastaglia, 2013, Journal of Neuroimmunology.

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome

S. Mallal, E. Phillips, Annalise M. Martin, 2006, Pharmacogenetics and genomics.

Metabolic Complications Associated with HIV Protease Inhibitor Therapy

D. Nolan, 2012, Drugs.

Clinical and immunogenetic correlates of abacavir hypersensitivity

S. Mallal, R. Kaul, S. Knowles, 2005, AIDS.

Cytokine Profiling in Abacavir Hypersensitivity Patients

I. James, S. Mallal, E. Phillips, 2008, Antiviral therapy.

Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?

M. John, S. Mallal, G. Watts, 2003, QJM : monthly journal of the Association of Physicians.

Randomized, Controlled, 48‐Week Study of Switching Stavudine and/or Protease Inhibitors to Combivir/Abacavir to Prevent or Reverse Lipoatrophy in HIV‐Infected Patients

C. Moore, M. John, I. James, 2003, Journal of acquired immune deficiency syndromes.

Extensive small-angle X-ray scattering studies of blood coagulation factor VIIa reveal interdomain flexibility.

D. Svergun, B. Vestergaard, J. Bukrinsky, 2010, Biochemistry.

Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study

S. Mallal, H. Furrer, M. Cavassini, 2008, Antiviral therapy.

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.

S. Mallal, Annalise M. Martin, D. Nolan, 2005, Tissue antigens.

The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.

M. John, S. Mallal, S. Gaudieri, 2012, Sexual health.

Light and electron microscopy findings in subcutaneous fat antiretroviral treated and HIV-infected patients

M. John, S. Mallal, D. Nolan, 2000 .

Hospitalizations in a cohort of HIV patients in Australia, 1999–2007

H. Wand, M. Law, D. Nolan, 2010, AIDS.

Use of alcohol, nicotine and other drugs in the Western Australian HIV Cohort study.

M. John, S. Mallal, M. Lucas, 2012, Sexual health.

HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.

S. Mallal, C. Mamotte, D. Nolan, 2007, Tissue antigens.

Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.

D. Cooper, A. Kelleher, S. Emery, 2008, The Journal of infectious diseases.

Carriage of HLA-B*5701 and a haplotypic Hsp70-Hom variant is associated with a Class I MHC-restricted hypersensitivity response to abacavir

I. James, F. Christiansen, S. Mallal, 2004 .

HIV/AIDS. HIV: experiencing the pressures of modern life.

I. James, S. Mallal, D. Nolan, 2005, Science.

The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.

S. Mallal, D. Nolan, 2004, Journal of HIV therapy.

Chorea associated with persistent low-level viremia in a patient living with HIV: a case report

M. John, D. Nolan, GK Rajakaruna, 2020, Journal of virus eradication.

Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy

C. Moore, M. John, I. James, 2003, AIDS.

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

K. Williams, G. Graham, E. Phillips, 2012, Internal medicine journal.

Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

David Nolan, Simon Mallal, S. Mallal, 2003, Journal of HIV therapy.

Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy

I. James, S. Mallal, P. Klenerman, 2009, Hepatology.

The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort

I. James, F. Christiansen, F. Mastaglia, 2013, Journal of Neuroimmunology.

Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation

David Nolan, Ian James, Simon Mallal, 2007, Journal of Virology.

Host MHC influences susceptibility to hypersensitivity reactions to two drugs commonly used in HIV therapy

C. Moore, I. James, F. Christiansen, 2005 .

Genetic factors predicting abacavir hypersensitivity and tolerance in HLA-B*5701 positive individuals

I. James, S. Mallal, J. Montaner, 2008 .

No evidence of mitochondrial DNA depletion in peripheral white blood cells after three to 12 months of HAART

S. Mallal, D. Nolan, E. McKinnon, 2002 .

Adaptive Interactions between HLA and HIV-1: Highly Divergent Selection Imposed by HLA Class I Molecules with Common Supertype Motifs

D. Heckerman, R. Haubrich, M. John, 2010, The Journal of Immunology.